


Diagnostic accuracy of natriuretic peptide screening for left ventricular systolic dysfunction in the community: systematic review and meta-analysis

Clare R. Goyder^{1*} , Andrea K. Roalfe¹, Nicholas R. Jones¹, Kathy S. Taylor¹, Charles D. Plumptre², Olivia James³, Thomas R. Fanshawe¹, F D Richard Hobbs¹ and Clare J. Taylor¹

¹Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK; ²Nuffield Department of Medicine, University of Oxford, Oxford, UK; and ³Clinical Medical School, University of Oxford, Level 3, John Radcliffe Hospital, Oxford, UK

Abstract

Aims Heart failure (HF) is a global health burden and new strategies to achieve timely diagnosis and early intervention are urgently needed. Natriuretic peptide (NP) testing can be used to screen for left ventricular systolic dysfunction (LVSD), but evidence on test performance is mixed, and international HF guidelines differ in their recommendations. Our aim was to summarize the evidence on diagnostic accuracy of NP screening for LVSD in general and high-risk community populations and estimate optimal screening thresholds.

Methods We searched relevant databases up to August 2020 for studies with a screened community population of over 100 adults reporting NP performance to diagnose LVSD. Study inclusion, quality assessment, and data extraction were conducted independently and in duplicate. Diagnostic test meta-analysis used hierarchical summary receiver operating characteristic curves to obtain estimates of pooled accuracy to detect LVSD, with optimal thresholds obtained to maximize the sum of sensitivity and specificity.

Results Twenty-four studies were identified, involving 26 565 participants: eight studies in high-risk populations (at least one cardiovascular risk factor), 12 studies in general populations, and four in both high-risk and general populations combined. For detecting LVSD in screened high-risk populations with N-terminal prohormone brain natriuretic peptide (NT-proBNP), the pooled sensitivity was 0.87 [95% confidence interval (CI) 0.73–0.94] and specificity 0.84 (95% CI 0.55–0.96); for BNP, sensitivity was 0.75 (95% CI 0.65–0.83) and specificity 0.78 (95% CI 0.72–0.84). Heterogeneity between studies was high with variations in positivity threshold. Due to a paucity of high-risk studies that assessed NP performance at multiple thresholds, it was not possible to calculate optimal thresholds for LVSD screening in high-risk populations alone. To provide an indication of where the positivity threshold might lie, the pooled accuracy for LVSD screening in high-risk and general community populations were combined and gave an optimal cut-off of 311 pg/mL [sensitivity 0.74 (95% CI 0.53–0.88), specificity 0.85 (95% CI 0.68–0.93)] for NT-proBNP and 49 pg/mL [sensitivity 0.68 (95% CI 0.45–0.85), specificity 0.81 (0.67–0.90)] for BNP.

Conclusions Our findings suggest that in high-risk community populations NP screening may accurately detect LVSD, potentially providing an important opportunity for diagnosis and early intervention. Our study highlights an urgent need for further prospective studies, as well as an individual participant data meta-analysis, to more precisely evaluate diagnostic accuracy and identify optimal screening thresholds in specifically defined community-based populations to inform future guideline recommendations.

Keywords Biomarkers; Screening; Left ventricular systolic dysfunction; Natriuretic peptides

Received: 26 February 2021; Revised: 13 June 2022; Accepted: 30 January 2023

*Correspondence to: Clare R. Goyder, Nuffield Department of Primary Care Health Sciences, University of Oxford, Radcliffe Observatory Quarter, Woodstock Road, Oxford OX2 6GG, UK. Email clare.goyder@phc.ox.ac.uk

Introduction

Approximately 40 million people worldwide are living with heart failure (HF), representing a major public health burden,^{1,2} but treatment can improve quality of life and survival and reduce hospitalizations.^{3,4} Detecting HF in the community, especially in the early stages, to achieve timely diagnosis is an urgent research priority.^{5–7} There is reliable evidence that treatment with renin–angiotensin–aldosterone system (RAAS) inhibitors, titrated to the appropriate dose, can limit progression from left ventricular systolic dysfunction (LVSD) to HF.^{8–11} Screening is one potential route to detect LVSD and provides an important opportunity for early intervention.

Echocardiography, and more recently cardiac magnetic resonance imaging (MRI), can accurately identify patients with LVSD, but these strategies are not feasible as general population screening tools due to poor cost-effectiveness. One potential screening strategy is an initial natriuretic peptide (NP) blood test with subsequent echocardiography or MRI performed only in patients with raised NP levels. There is evidence supporting the role of NP testing in the diagnosis of HF in symptomatic patients and limited evidence in treatment optimization.^{12,13} However, the St Vincent's Screening to Prevent Heart Failure (STOP-HF) trial was the first randomized controlled trial to indicate that an NP-guided screening approach in asymptomatic people, linked to targeted prevention, reduced the progression of asymptomatic LVSD and the development of HF in high-risk groups.¹³

Globally, HF guidelines differ in their recommendations on NP screening to detect LVSD: European guidelines do not currently advocate screening, whereas North American guidelines recommend NP screening in high-risk patients but do not specify optimal NP screening thresholds or make any recommendation for general populations.^{4,14–17} Moreover, the overall performance of NP as a screening tool for LVSD remains unclear. How NP performs as a screening test across different populations (e.g. high-risk vs. general community populations) and what NP threshold is appropriate for biomarker-based screening is also uncertain. Previous systematic reviews have focused on the accuracy of NP as a diagnostic tool for HF in symptomatic, presenting patients,^{17,18} or analysed accuracy in combined diagnostic and screening studies.^{18,19} Those reviews that have assessed NP performance in a screening context have often combined primary and secondary care studies, rather than focussing specifically on screening in the community.^{18,20,21}

The aim of this study was to provide an up-to-date summary of the accuracy of NP screening for LVSD, considering both brain natriuretic peptide (BNP) and N-terminal prohormone BNP (NT-proBNP) compared with echocardiography and cardiac MRI in community populations, and to determine the optimal NP screening threshold.

Methods

This systematic review and meta-analysis protocol has been prospectively registered in PROSPERO (registration number: CRD42018087498) and separately published.²² This review has been produced in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines and recommendations from the Cochrane Collaboration.²³ The full search strategy is available in *Appendix S1*.

This study was discussed with our patient and public involvement group, who agreed that improving the detection of HF was a research priority. The group was familiar with the consequences of delayed diagnosis, some with personal experience, and welcomed more research on screening.

Search methodology

We searched Ovid Medline, Embase, Cochrane Database of Systematic Reviews and Cochrane Central Register of Controlled Trials, Cochrane CENTRAL, DARE, and Science Citation Index from inception on 17 April 2019 and updated the search on 13 August 2020. We did not employ a study design filter or add any language restriction. We searched reference lists to identify more publications. Screening was carried out by two reviewers independently (CG and either CP, NJ, or OJ). Disagreements were resolved by discussion or referral to a third reviewer (CT).

Screening methodology

We included studies of over 100 adult participants in a community setting to limit bias from small studies. Included studies compared the performance of NP testing with either echocardiography or cardiac MRI for the detection of LVSD. We included studies that recruited screened community populations. Community screening may identify patients with preclinical HF, such as asymptomatic LVSD, also termed stage B HF. Screening may also detect patients with clinical HF who had not been appropriately diagnosed previously. Given this, we took a pragmatic approach and included all patients who had participated in screening studies.

We excluded studies of patients recruited through secondary care, such as cardiology clinics, and studies presenting insufficient data to construct 2 × 2 tables. We also excluded duplicate datasets, selecting the papers that most closely aligned with inclusion criteria or were most recently published. The inclusion and exclusion criteria for participants in included studies are found in *eTable 1*.

Target condition

Consistent with the overall aim of community screening, LVSD was defined broadly by evidence of reduced ejection fraction (EF) including either quantitative or narrative descriptions of reduced systolic function and/or other echocardiographic parameters. An EF cut-off of 40% (or nearest) was selected in studies reporting results for more than one EF threshold.

Data extraction and quality assessment

Data extraction was performed independently by two reviewers (CG and either CP, NJ, or OJ).²² A risk of bias template incorporating QUADAS-2 criteria was used to assess methodological quality.²⁴ Disagreements were discussed or referred to a third reviewer (CT). Diagnostic accuracy data were extracted from all studies,²⁵ and 2 × 2 tables were constructed in accordance with current reporting guidelines, at all NP thresholds reported.²⁶

Statistical analyses

Meta-analysis was performed where there were at least four studies with available data. Subgroup analyses were performed for both types of NP (to include BNP and NT-proBNP) as well as high-risk and general populations. High-risk populations were defined as having at least one cardiovascular (CV) risk factor or ischaemic heart disease (IHD) or were selected non-general populations, such as cohorts of nursing home residents or patients with chronic obstructive pulmonary disease (COPD), as the overlap between COPD and HF is known to be high.²⁷

To visually explore the variation in diagnostic accuracy, sensitivity and specificity forest plots with 95% confidence intervals (CIs) for both types of NP, ordered by each threshold reported, were produced in RevMan 5.3.²⁸ Where data included multiple thresholds, R version 3.5.3 (*diagmeta* package)²⁹ was used to produce SROC curves in relation to the positivity threshold with estimation of the single threshold that maximized the sum of sensitivity and specificity.³⁰ A logistic distribution for threshold within the diseased and non-diseased groups was assumed, and NP levels were log-transformed due to skewness. If there were insufficient data to generate SROCs with multiple thresholds, hierarchical SROC curves with 95% CI and prediction regions were drawn (Stata version 15.0, *metandi* command) using the lowest threshold for each study.³¹ Some studies did not report data for the combined group of men and women together with the threshold used to define positivity. Therefore, for our primary analysis, we decided to include all the available

data for men and totals (i.e. men and women combined if reported, and otherwise men only). Sensitivity analysis was carried out to analyse the available data on women and totals (i.e. men and women combined if reported, and otherwise women only) to explore whether there were any differences that resulted from this analysis decision. Sensitivity analyses were also carried out to compare studies that excluded participants with a previous diagnosis of LVSD with studies that did not and to examine whether there was any difference in accuracy in studies that described participants as entirely asymptomatic compared with other included studies.

Results


From 3131 records (*Figure 1*), 24 studies presented accuracy data for NP screening to detect LVSD, involving 26 565 participants^{32–55}; all included studies were cross-sectional. The included studies, with population characteristics and the lowest threshold reported, are summarized in *Table 1*. Full data for all thresholds including prevalence are available in *eTable 2*. Details of inclusion and exclusion criteria are listed in *eTable 1*; included studies were published over 16 years between 1998 and 2014.

Characteristics of included studies

Eight studies included data on only high-risk populations,^{32–39} 12 included only general populations,^{37,40–50} and four included data on high-risk and general populations.^{51–54} Nine studies assessed NT-proBNP only,^{32–34,40,43,46,47,51,54} and nine studies assessed BNP only; one of these used a point-of-care BNP test, Biosite®,³⁵ whereas all other tests were processed in a laboratory. Six studies evaluated performance in both biomarkers.^{37,39,42,43,48,52} All studies used echocardiography as the comparator except one that used cardiac MRI.⁴⁵ Subgroup sample sizes corresponding to each meta-analysis were smaller for high-risk populations with NT-proBNP ($n = 4193$) and BNP ($n = 2940$), with larger groups seen in the general populations, with NT-proBNP ($n = 13 416$) and BNP ($n = 12 970$).

Studies differed in the inclusion criteria for the ages of participants they recruited. General populations included participants of younger ages, whereas high-risk populations were older (as summarized in *Table 1*).

Most included studies classified LVSD as reduced EF of either <40% or <50%. In two studies, the outcomes of diastolic dysfunction and LVSD were combined,^{32,40} and three studies used narrative descriptions of LVSD rather than quantitative measurements of EF.^{32,41,42}

Figure 1 PRISMA diagram flow of studies through the selection process.

The reported prevalence for studies presenting accuracy data for LVSD in total populations ranged from 0.4% to 12.9% (*eTable 2*).

There was some variability in how individual studies defined high-risk populations. Some studies categorised any participant who had more than one CV risk factor as high risk.^{37,38} One only included patients who had IHD in a high-risk group,⁵³ whereas another included post-myocardial infarction (MI) or IHD patients in combination with other risk factors.⁴⁷ There were no included studies that included cohorts of COPD patients; one high-risk study recruited from nursing homes.³⁹

Only seven studies described the population as completely asymptomatic.^{32,33,36–38,42,54} One study described the population as 'mostly asymptomatic'.⁵⁵ McDonagh *et al.* described the population as 50% symptomatic and 50% asymptomatic.⁵³ Of the remaining studies, the majority recruited randomly selected community populations and did not provide details of whether the participants reported any symptoms. Some described their population cohorts as 'healthy' without any data to explain this.⁴⁵ Two studies described participants as having a high proportion of symptomatic participants^{35,39} and one study recording only 22.2% as symptomatic.⁴³

Table 1 Characteristics of included studies reporting NP screening for LVSD.

Studies	Location	Natriuretic peptide	Number of participants	Age group (yrs)	Population subgroup	Lowest LVSD threshold(pg/ml)	Target condition
Abhayaratna 2006§ Betti 2009§	Canberra, Australia Unclear, Italy	NT-proBNP NT-proBNP	1229 1012	60–74 > = 67	General population High-risk	151 125	EF ≤ 40% and advanced DD-NEF Pooled systolic and moderate-severe DD† LVEF ≤ 50% LVEF ≤ 40%/LVEF ≤ 50%
Cosin Aguilar 2003 Costello-Boerrigter 2006	Valencia, Spain Olmsted County, Minnesota, USA	NT-proBNP BNP	203 1869	49–81 < 65	General population General population	215 12	LVSD EF < 55 or LVH††
De Lemos 2009	Dallas, Texas, USA	NT-proBNP BNP	1869 2429	< 65 18–64	General population General population	32 7.1	LVEF < 50% LVEF < 40%
Galasko 2005	London, UK	NT-proBNP NT-proBNP	2429 734	18–64 > = 45	General population General population	28.9 †	LVEF < 40% LVEF < 40%
Gavazzi 2014	Lombardy, Italy	NT-proBNP NT-proBNP	761 623	> = 45 55–80	High-risk High-risk	† †	LVEF < 45% LVEF < 50%
Goetze 2006 Groenning 2004	Copenhagen, Denmark Copenhagen, Denmark	NT-proBNP NT-proBNP	3497 672	> 55 > = 50	General population General population	144 351	LVSD LVEF < 35% LVSD LVEF < 40% LVSD LVEF < 45% LVSD LVEF < 50%
Hebert 2010 Hedberg 2004	Louisiana, USA Västerås, Sweden	BNP BNP	145 407	40–75 75	High risk General population	60 28	LVEF < = 54% LVSD based on wall motion index corresponding to LVEF < 40%
Hobbs 2004	England, UK	BNP BNP	133 307	> = 45 > = 45	High risk General population	103.8 103.8	LVSD < 40% LVSD < 40%
Lobos Bejarano 2012 Luchner 2000	Madrid, Spain Augsburg, Germany	NT-proBNP NT-proBNP	307 307	> = 45 > = 45	High risk General population	338 338	LVSD < 40% LVSD < 40%
Luers 2010 Lukowicz 2005 Mason 2013	Goettingen, Germany Augsburg, Germany North-East England, UK	BNP BNP NT-proBNP	542 1678 392	> 40 25–75 ≥ 65	High risk General population High risk	105 27 145	LVSD (defined as fractional shortening < 28%)/general population LVSD (LVEF < 50%) LVSD (EF < 40%) LVSD EF < 50%
McDonagh 1998	Glasgow, UK	NT-proBNP BNP	393 1252	≥ 65 25–74	High risk General population	1000 17.9	LVSD < 30%
Mureddu 2013	Lazio region, Italy	NT-proBNP NT-proBNP	435 1452	25–74 65–84	High risk General population	17.9 278	LVSD EF < 50
Murtagh 2012	Ireland	NT-proBNP BNP	814	65–84 > 40	General population High-risk	278 20	LVSD < 50% LVSD < 40%
Ng 2003	Leicestershire, UK	BNP NT-proBNP	1331 1331	45–80 45–80	General population General population	66 318	Definite systolic EF ≤ 35%
Smith 2000	Poole, Dorset, UK	BNP	155	> 70	General population	64.7	Reduced left ventricular ejection fraction/LVSD confirmed by echo
Vasan 2002	Framingham, Massachusetts, USA	BNP	3177	> 40	General population	21	

Population subgroup describes total (men plus women) except for *Galasko 2005 thresholds based on age/sex specific 97.5th percentiles: 100 pg/mL males aged 45–59; 164 pg/mL females aged 45–59; 172 pg/mL males aged > = 60; 225 pg/mL females age > = 60 †Gavazzi 2014 thresholds based on age/sex specific 95th percentiles (data not provided)§. LVSD data pooled with data on diastolic dysfunction. DD-NEF diastolic dysfunction LV EF (EF > 50%), ††DD diastolic dysfunction ††Left ventricular hypertrophy. The threshold shown in this table is the lowest threshold reported; all threshold data are reported in eTable 2.

Quality of included studies

The majority of studies had low or unclear risk of bias with <20% of ratings in the high-risk category (eFigure 1, eFigure 2). Studies recorded with high risk for patient selection generally excluded patients who had a previous MI even though this patient group may benefit from screening for LVSD.^{32,42,45} In reporting the index test, some studies presented incomplete data.^{44,49,55} Not all studies performed the reference test blinded to the index test,⁵⁵ and some failed to give information on how echocardiography was conducted.⁵³

Accuracy of NP to screen for LVSD in high-risk populations

Most studies of high-risk populations demonstrated a trade-off between sensitivity and specificity as shown in the forest plots for NT-proBNP and BNP (Figure 2A). For NT-proBNP (Figure 3A), the pooled sensitivity was 0.87 (95% CI 0.73–0.94) and specificity 0.84 (95% CI 0.55–0.96) for detecting LVSD in screened high-risk populations. For BNP in high-risk populations (Figures 2B and 3B) the pooled sensitivity was 0.75 (95% CI 0.65–0.83) and specificity 0.78 (95% CI 0.72–0.84).


Accuracy of NP to screen for LVSD in general populations

There was extensive variability in sensitivity and specificity for studies of general populations (eFigure 3), some of which was due to differences in reported threshold. For NT-proBNP in general populations (eFigure 4), the pooled sensitivity was 0.72 (95% CI 0.42–0.90) with specificity 0.82 (95% CI 0.60–0.93), and the optimal threshold was 274 pg/mL. For BNP in general populations, the pooled sensitivity was 0.62 (95% CI 0.32–0.85) with specificity 0.83 (95% CI 0.61–0.94) and optimal threshold 46 pg/mL (eFigure 1).


Optimal screening thresholds

It was not possible to calculate optimal thresholds for NP screening for LVSD in only high-risk populations as there were not enough studies of this population that provided data at multiple thresholds. However, the pooled accuracy of NT-proBNP in high-risk and general community populations combined (Figure 4) gave an optimal cut-off of 311 pg/mL with sensitivity of 0.74 (95% CI 0.53–0.88) and specificity 0.85 (95% CI 0.68–0.93). The pooled accuracy data for BNP (eFigure 6) yielded an optimal screening threshold for the detection of LVSD at 49 pg/mL with a sensitivity of 0.68 (95% CI 0.45–0.85) and a specificity of 0.81 (0.67–0.90).

Figure 2 (A) Paired sensitivity and specificity plot for NT-proBNP compared with echocardiography for detecting LVSD in screened high-risk populations. Thresholds are measured in pg/mL, and studies are ordered by NP threshold. Threshold were age specific for Gavazzi et al., based on 95th percentiles (data not provided) and for Galasko et al., based on 97.25th percentiles (100 pg/mL males aged 45–59; 164 pg/mL females aged 45–59; 172 pg/mL males aged >= 60; 225 pg/mL females age >= 60). (B) Paired sensitivity and specificity plot for BNP compared with echocardiography for detecting LVSD in screened high-risk populations. Thresholds are measured in pg/mL, and studies are ordered by NP threshold.




(A)



(B)

Figure 3 (A) SROC curves of NT-proBNP compared with echocardiography for detecting LVSD in screened high-risk populations. (B) SROC curves of BNP compared with echocardiography for detecting LVSD in screened high-risk populations.




Sensitivity analysis

Sensitivity analysis demonstrated that overall NP performance was similar when studies that excluded participants with a previous diagnosis of LVSD were compared with studies that did not (*eFigures 7–10*). Seven of the included LVSD studies described the screened population as entirely asymptomatic and sensitivity analysis examined whether there were any differences when results of these studies were compared to the other included studies; performance of NP screening was comparable across both groups. Sensitivity analysis was also performed to exclude studies identified as having high risk of bias (*eFigures 13–16*), and no major differences in performance were noted. We analysed the available data on women and totals (i.e. men and women combined if reported, and otherwise women only) in a further sensitivity analysis, as we had decided to base our primary analysis on all the available data for men

and totals (i.e. men and women combined if reported, and otherwise men only) because not all studies reported data for the combined group of men and women together (*eFigures 17 and 18*). We felt this analysis was particularly relevant given sex-specific differences in the manifestation of CV diseases including HF.⁵⁶ There was a drop in the sensitivity of NT-proBNP from 0.72 (95% CI 0.42–0.90) to 0.68 (95% CI 0.36–0.89) and for BNP from 0.62 (95% CI 0.32 to 0.85) to 0.59 (95% CI 0.30–0.83), whereas specificity was similar [NT-proBNP 0.82 (95% CI 0.60–0.93) vs. 0.83 (95% CI 0.63–0.94)] and BNP 0.83 (95% CI 0.61–0.94) vs. 0.82 (95% CI 0.64–0.90). The differences in sensitivity were small, however, and in the context of wide CIs, they may not be clinically meaningful.

One of the included studies, Mason et al.³⁹ used only one NT-proBNP threshold set at 1000 pg/mL (which was higher than most other included studies), and no other results at lower thresholds were included. A sensitivity analysis was

Figure 4 SROC curve of NT-proBNP at multiple thresholds compared with echocardiography for detecting LVSD in screened general and high-risk populations combined.



therefore performed to examine whether excluding this study affected the pooled accuracy results (*eFigure 19*); there was no significant change in the pooled sensitivity and specificity for detecting LVSD in screened high-risk populations with Mason *et al.* excluded.

Discussion

We found that in studies recruiting high-risk community populations, screening with NP testing accurately detected LVSD: NT-proBNP testing demonstrated a high pooled sensitivity of 0.87 (95% CI 0.73–0.94) and specificity of 0.84 (95% CI 0.55–0.96). In studies of general community populations, the pooled sensitivity of NT-proBNP to detect LVSD was lower at 0.72 (95% CI 0.42–0.90) with specificity 0.82 (95% CI 0.60–0.93). The pooled accuracy of NT-proBNP in high-risk and general community populations combined gave an optimal cut-off of 311 pg/mL with sensitivity of 0.74 (95% CI 0.53–0.88) and specificity 0.85 (95% CI 0.68–0.93). The pooled accuracy data for BNP yielded an optimal screening threshold for the detection of LVSD at 49 pg/mL with a sensitivity of 0.68 (95% CI 0.45–0.85) and a specificity of 0.81 (0.67–0.90).

Comparison with previous studies

We compared our results with similar studies exploring the use of NP testing in screening non-presenting patients for LVSD. Although previous systematic reviews have included NP screening, studies from secondary and community populations have been combined,^{20,57} or community settings were analysed but specifically in nursing homes only.⁵⁸ Ewald *et al.* calculated a pooled diagnostic odds ratio (DOR) of 9.3 (95% CI 4.7–17.4) for NT-proBNP screening for severe LVSD.²⁰ Based on the pooled estimate of sensitivity and specificity, our DOR for NT-proBNP to detect LVSD is higher at 42, but there is more heterogeneity within our studies. A recent individual patient data study has also developed and validated a prediction model that identified older patients with HF.⁵⁹ The clinical model improved with the addition of NT-proBNP and modelling in combination with NP screening may provide the most accurate screening strategy.

Our results for optimal screening thresholds are consistent with previous research in this area. For general and high-risk populations combined, the optimal threshold for BNP was 49 pg/mL in our study. This aligns closely with the STOP-HF study that used BNP \geq 50 pg/mL as a cut-off for intervention, and it is the results from this study that underpin the current North American guideline recommendations.^{13,14} Moreover, findings from another meta-analysis of screening studies that

combined primary and secondary care studies found that the optimal sensitivity was achieved when BNP was below the cut point of 50 pg/mL.⁵⁷ To put this in context, this level of BNP threshold is similar to 2021 European Society of Cardiology (ESC) guidelines for the diagnosis of chronic HF for patients who present with symptoms in the non-acute settings in which the upper limit of normal for BNP is 35 pg/mL (125 pg/mL for NT-proBNP) although these do not refer to screened community populations.⁴ However, the optimal threshold for NT-proBNP in our analysis of 311 pg/mL was notably higher than the current recommended ESC guideline cut-off of 125 pg/mL. NT-proBNP is increasingly used in favour of BNP in some countries, so agreement on an optimal threshold is needed.⁶⁰ A recent German study found that there was an age-related incremental increase in NT-proBNP levels in asymptomatic older adults, with significant sex differences also observed.⁶¹ The Heart Failure Association of the ESC has published practical guidance on the use and interpretation of NP tests, including in the context of screening.⁶²

Overall, there is a paucity of HF diagnostic accuracy studies in screened community-based populations. More research has been conducted in acute HF with more published diagnostic accuracy data available. A meta-analysis by Roberts et al., which informed the current National Institute for Health and Care Excellence acute HF guideline, pooled data from 37 acute HF diagnostic accuracy studies, including 15 263 NP test results, to evaluate NP test performance.⁶³ They found the NP thresholds defined in the ESC HF guideline 2012 performed well, particularly at the lower threshold (BNP < 100 pg/mL, NT-proBNP < 300 pg/mL) for ruling out acute HF.⁶³ A similar increase in the number and quality of community-based screening studies is needed to further evaluate the role of NP testing to detect or rule out LVSD.⁴

Implications for policy and practice

There is an urgent need for further prospective studies as well as an individual participant data meta-analysis to more precisely evaluate diagnostic accuracy and identify optimal screening thresholds in specifically defined sub-populations within the community, including comparing performance by EF, in populations who are aged under or over 65 years, and this should include comparisons of accuracy in men and women. Biological variables such as BMI and renal function also need to be better understood in a screening context.

Current policy on the use of NP screening to detect LVSD varies globally. European guidelines do not recommend NP screening, whereas North American guidelines advocate screening without specifying where the positivity threshold should be set.¹⁴ Our results provide evidence to support NP screening in high-risk populations to detect LVSD and contribute to the evidence base on screening thresholds.

The performance of NP screening to detect LVSD is comparative in accuracy to some cancer screening approaches such as faecal immunochemical testing (FIT) for haemoglobin to detect colorectal cancer. The FIT test is now integrated into the UK national bowel cancer screening programme.⁶⁴

Screening in healthcare remains a contentious issue. The costs and benefits of any screening programme would need to be considered on a national level. In many European countries, echocardiography services are already under strain and the potential for overdiagnosis when imaging large numbers of people is considerable. Future research should investigate whether false positive rates could be reduced with refinement of target populations, potentially through improved risk prediction, as well as to explore the acceptability of screening from a patient perspective.⁶⁵ The burden on the patient and healthcare system needs to be outweighed by improvements in mortality and quality of life and reduced costs of caring for patients with advanced HF, which may result from earlier diagnosis and treatment. Future research needs to examine both the impact of NP screening for LVSD on patient outcomes and the resources required for management of screen-detected patients, including up-titration of medications.⁶⁶

Strengths and limitations

To our knowledge, this is the first systematic review to focus on the diagnostic accuracy of NP testing in screened community populations alone for the detection of LVSD to compare performance in both high-risk and general populations and to analyse NP thresholds used in screening studies. Decisions regarding inclusion criteria were based on a pragmatic approach underpinned by clinical experience of community diagnostics. To increase applicability to a broad range of clinical contexts, we expanded on the definition of high-risk populations that were used in STOP-HF.¹³ This review has been produced in accordance with the PRISMA guidelines and the Cochrane Handbook for Systematic Reviews of Diagnostic Test Accuracy.²³ There was significant heterogeneity among the included studies due to variation in the included clinical populations, definition of LVSD used by investigators, and disparities in reporting of diagnostic accuracy parameters at different NP thresholds. Study populations differed in the ages of included participants, presence of symptoms, and the prevalence of LVSD. We were unable to undertake planned subgroup analysis by age due to the wide variation in age ranges recruited across studies (see *Table 1*, *eTable 1*, and *eTable 2* for age definitions) and the unavailability of individual patient data. Attempts were made to mitigate for this by analysing data separately for high-risk and general populations, an approach not taken by most previous systematic reviews that have focussed on NP screening, and examined the population as a whole.^{20,21} We included all studies

from screened community populations but only some studies ($n = 7$, 29%) described participants as entirely asymptomatic. Many patients with HF describe being unaware of symptoms initially, particularly when these are very mild, and therefore do not present to a healthcare professional.⁵ The presence or absence of symptoms is therefore variable, and the included studies are aligned with the real-world experience of community screening where there might be symptomatic patients still presenting for a screening test, particularly if symptoms are mild.

The definitions of LVSD are listed under target condition in *Table 1*, *eTable 1*, and *eTable 2*. As the overall aim of community screening is to identify previously undetected LVSD, we chose to include both narrative and quantitative descriptions of reduced left ventricular EF although this may have contributed to the clinical heterogeneity. We planned to analyse test performance by EF (e.g. <40%, <50%), but there were too few studies to enable this subgroup analysis to be performed.

The different NP thresholds reported by included studies are also listed in *Table 1*, *eTable 1*, and *eTable 2*, all forest plots were also ordered by threshold so that different studies that reported performance at similar thresholds were grouped together. We have attempted to provide an estimation of where optimal screening thresholds might lie. The statistical model that was used to pool sensitivity and specificity to provide a summary estimate is different to the model that is required to identify the optimal threshold.³⁰ Fitting this model requires studies to report results at multiple thresholds, and there were not enough such studies in the subgroup of studies in high-risk populations to allow this. The inability to recommend an optimal screening threshold in high-risk populations is a major study limitation. To provide an indication of where the appropriate positivity threshold might lie, we estimated an optimal threshold from the pooled high-risk and general population studies combined. We acknowledge that this also limits the current clinical applicability of the findings although identifying this evidence gap is an important finding and provides a focus for future research that can build on this more general exploration of the accuracy of NP screening for LVSD.

Conclusions

In high-risk community populations, it is likely that NP screening may accurately detect LVSD. Given the huge public health burden of missed HF diagnoses in the community, this finding presents a potentially important opportunity for diagnosis and early intervention. Our study highlights an urgent need for further prospective studies, as well as an individual participant data meta-analysis, to evaluate diagnostic accuracy more precisely, to identify optimal screening thresholds in specifically defined sub-populations within the community,

and to further examine the impact of NP screening on both general and high-risk populations.

Acknowledgements

We thank medical librarian Nia Roberts for her help with the systematic search and update. We thank the Heart Disease Patient Advisory Group in the Nuffield Department of Primary Care Health Sciences, University of Oxford, for their input into this project. CG wishes to thank Professor Anthony Harnden and Professor Christian Mallen for their support.

Conflict of interest

All authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf and declare: CT reports speaker fees from Vifor and Novartis and non-financial support from Roche outside the submitted work. FDRH reports personal fees and other from Novartis and Boehringer Ingelheim and grants from Pfizer outside the submitted work. CG and the other authors have nothing to disclose.

Funding

This work was supported by Wellcome Trust Doctoral Fellowships [CG 203921, NJ 203921]. AR is funded by the NIHR Oxford Biomedical Research Centre, Oxford University Hospitals NHS Foundation Trust. KST receives funding from the NIHR Programme Grants for Applied Research. TF receives funding from the National Institute for Health Research Community Healthcare MedTech and In Vitro Diagnostics Co-operative (MIC) at Oxford Health NHS Foundation Trust. RH acknowledges part-funding from the NIHR School for Primary Care Research, the NIHR Collaboration for Leadership in Health Research and Care (CLARHC) Oxford, the NIHR Oxford BRC, and the NIHR Oxford MIC. CT is an NIHR Academic Clinical Lecturer. This work is part of the Long Term Condition theme of the NIHR Oxford MIC, which is co-lead by RH and CT. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR, or the Department of Health and Social Care.

Supporting information

Additional supporting information may be found online in the Supporting Information section at the end of the article.

Appendix S1. Search Strategy.

References

- GBD 2015 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990–2015: a systematic analysis for the global burden of disease study 2015. *Lancet*. 2016; **388**: 1545–1602.
- Mamas MA, Sperrin M, Watson MC, Coutts A, Wilde K, Burton C, Kadam UT, Kwok CS, Clark AB, Murchie P, Buchan I, Hannaford PC, Myint PK. Do patients have worse outcomes in heart failure than in cancer? A primary care-based cohort study with 10-year follow-up in Scotland. *Eur J Heart Fail*. 2017; **19**: 1095–1104.
- National Institute for Health and Care Excellence. Chronic heart failure in adults: diagnosis and management (NICE guideline NG106) 2018. <https://www.nice.org.uk/guidance/ng106> [Accessed 16 October 2019]
- ESC Scientific Document Group. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: developed by the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) with the special contribution of the heart failure association (HFA) of the ESC. *Eur Heart J*. 2021; **42**: 3599–3726.
- Taylor CJ, Hobbs FDR, Marshall T, Leyva-Leon F, Gale N. From breathless to failure: symptom onset and diagnostic meaning in patients with heart failure—a qualitative study. *BMJ Open*. 2017; **7**: 1–8.
- Bottle A, Kim D, Aylin P, Cowie MR, Majeed A, Hayhoe B. Routes to diagnosis of heart failure: observational study using linked data in England. *Heart*. 2018; **104**: 600–605.
- Taylor CJ, Ordóñez-Mena JM, Roalfe AK, Lay-Flurrie S, Jones NR, Marshall T, Hobbs FDR. Trends in survival after a diagnosis of heart failure in the United Kingdom 2000–2017: population based cohort study. *BMJ*. 2019; **364**: 1–10.
- Roger VL. Asymptomatic left ventricular dysfunction: to screen or not to screen? *JACC Hear Fail*. 2016; **4**: 249–251.
- Echouffo-Tcheugui JB, Erqou S, Butler J, Yancy CW, Fonarow GC. Assessing the risk of progression from asymptomatic left ventricular dysfunction to overt heart failure: a systematic overview and meta-analysis. *JACC Hear Fail*. 2016; **4**: 237–248.
- Benedict CR, Francis GS, Shelton B, Johnstone DE, Kubo SH, Kirilin P, Nicklas J, Liang C-S, Konstam MA, Greenberg B, Yusuf S, The SOLVD Investigators. Effect of long-term enalapril therapy on neurohormones in patients with left ventricular dysfunction. *Am J Cardiol*. 1995; **75**: 1151–1157.
- Goldberg LR, Jessup M. Stage B heart failure: management of asymptomatic left ventricular systolic dysfunction. *Circulation*. 2006; **113**: 2851–2860.
- McLellan J, Bankhead CR, Oke JL, Hobbs FDR, Taylor CJ, Perera R. Natriuretic peptide-guided treatment for heart failure: a systematic review and meta-analysis. *BMJ Evidence-Based Med*. 2020; **25**: 33–37.
- Gallagher J, Campbell P, Ledwidge M, Ledwidge M, Gallagher J, Conlon C, Tallon E, O'Connell E, Dawkins I, Watson C, O'Hanlon R, Birmingham M, Patle A, Badabhagn MR, Murtagh G, Voon V, Tilson L, Barry M, McDonald L, Maurer B, McDonald K, Connell EO, Dawkins I, Watson C, Hanlon RO, Birmingham M, Patle A, Badabhagn MR, Murtagh G, Voon V, Tilson L, Barry M, McDonald L, Maurer B, McDonald K, O'Connell E, Dawkins I, Watson C, O'Hanlon R, Birmingham M, Patle A, Badabhagn MR, Murtagh G, Voon V, Tilson L, Barry M, McDonald L, Maurer B, McDonald K. Natriuretic peptide-based screening and collaborative care for heart failure: the STOP-HF randomized trial. *JAMA - J Am Med Assoc*. 2013; **310**: 66–74.
- Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE, Colvin MM, Drazner MH, Filippatos GS, Fonarow GC, Givertz MM, Hollenberg SM, Lindenfeld JA, Masoudi FA, McBride PE, Peterson PN, Stevenson LW, Westlake C. *ACC/AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the management of heart failure: A report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of Amer*, *Circulation*, Vol. **136**, 2017. Lippincott Williams and Wilkins; 2017. p e137–e161.
- Ezekowitz JA, Meara EO, McDonald MA, Abrams H, Chan M, Ducharme A, Giannetti N, Grzeslo A, Hamilton PG, Heckman GA, Howlett JG, Koshman SL, Pharm D, Lepage S, Mckelvie RS, Moe GW, Rajda M, Swiggum E, Virani SA, Zieroth S, Abdul P, Cohen-solal A, Astous MD, De S, Estrella-holder E, Fremes S, Green L, Haddad H, Harkness K, Hernandez AF, Kouz S, Masoudi FA, Ross HJ, Roussin A, Sussex B. 2017 comprehensive update of the Canadian cardiovascular society guidelines for the management of heart failure. *Can J Cardiol*. 2017; **33**: 1342–1433.
- Mant J, Doust J, Roalfe A, Barton P, Cowie M, Glasziou P, Mant D, McManus R, Holder R, Deeks J, Fletcher K, Qume M, Sohanpal S, Sanders S, Hobbs F. Systematic review and individual patient data meta-analysis of diagnosis of heart failure, with modelling of implications of different diagnostic strategies in primary care. *Health Technol Assess (Rockv)*. 2009; **13**: 1–207 iii.
- Doust JA, Glasziou PP, Pietrzak E, Dobson AJ. A systematic review of the diagnostic accuracy of natriuretic peptides for heart failure. *Arch Intern Med*. 2004; **164**: 1978.
- Booth RA, Hill SA, Don-Wauchope A, Santaguida PL, Oremus M, McKelvie R, Balion C, Brown JA, Ali U, Bustamam A, Soheli N, Raina P. Performance of BNP and NT-proBNP for diagnosis of heart failure in primary care patients: a systematic review. *Heart Fail Rev*. 2014; **19**: 439–451.
- Hildebrandt P, Collinson PO, Doughty RN, Fuat A, Gaze DC, Gustafsson F, Januzzi J, Rosenberg J, Senior R, Richards M. Age-dependent values of N-terminal pro-B-type natriuretic peptide are superior to a single cut-point for ruling out suspected systolic dysfunction in primary care. *Eur Heart J*. 2010; **31**: 1881–1889.
- Ewald B, Ewald D, Thakkinstian A, Attia J. Meta-analysis of B type natriuretic peptide and N-terminal pro B natriuretic peptide in the diagnosis of clinical heart failure and population screening for left ventricular systolic dysfunction. *Intern Med J*. 2008; **38**: 101–113.
- Latour-Pérez J, Covés-Orts FJ, Abad-Terrado C, Abaira V, Zamora J. Accuracy of B-type natriuretic peptide levels in the diagnosis of left ventricular dysfunction and heart failure: a systematic review. *Eur J Heart Fail*. 2006; **8**: 390–399.
- Goyder CR, Hobbs FDR, Roalfe AK, Jones NR, Taylor CJ, Taylor KS, Plumpton CD. Diagnostic accuracy and clinical impact of natriuretic peptide screening for the detection of heart failure in the community: a protocol for systematic review and meta-analysis. *Wellcome Open Res*. 2019; **4**: 169.
- Macaskill P, Gatsonis C, Deeks JJ, Harbord RMTY. Analysing and presenting results. In Deeks J. J., Bossuyt P. M., Gatsonis C., eds. *Cochrane handbook for systematic reviews of diagnostic test accuracy version 1.0*, Vol. **2010**. The Cochrane Collaboration; 2010. Available from: <http://srdta.cochrane.org/>. Accessed 5 Oct 2021.
- Whiting PF, Rutjes AW, Westwood ME, Mallett S, Deeks JJ, Reitsma JB, Leeflang MM, Sterne JA, Bossuyt PM, Q2 group. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. *Ann Intern Med*. 2011; **155**: 529–536.
- Taylor KS, Mahtani KR, Aronson JK. Extracting data from diagnostic test accuracy studies for meta-analysis. *BMJ Evidence-Based Med*. 2021; **26**: 19–21.
- Cohen JF, Korevaar DA, Altman DG, Bruns DE, Gatsonis CA, Hooft L, Irwig

- L, Levine D, Reitsma JB, De Vet HCW, Bossuyt PMM. STARD 2015 guidelines for reporting diagnostic accuracy studies: explanation and elaboration. *BMJ Open*. 2016; **6**: 1–17.
27. Le Jemtel TH, Padeletti M, Jelic S. Diagnostic and therapeutic challenges in patients with coexistent chronic obstructive pulmonary disease and chronic heart failure. *J Am Coll Cardiol*. 2007; **49**: 171–180.
 28. Review Manager (RevMan) Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
 29. Rücker G, Steinhauser S, Kolampally S SG. Diagma: meta-analysis of diagnostic accuracy studies with several cutpoints. 2018. <https://cran.r-project.org/web/packages/diagma/index.html>. Accessed 10 Oct 2019.
 30. Steinhauser S, Schumacher M, Rücker G. Modelling multiple thresholds in meta-analysis of diagnostic test accuracy studies. *BMC Med Res Methodol*. 2016; **16**: 1–15 Accessed 16th October 2019.
 31. StataCorp. 2017. Stata statistical software: release 15. College Station TSL.
 32. Betti I, Castelli G, Barchielli A, Beligni C, Boscherini V, De Luca L, Messeri G, Gheorghide M, Maisel A, Zuppiroli A. The role of N-terminal PRO-brain natriuretic peptide and echocardiography for screening asymptomatic left ventricular dysfunction in a population at high risk for heart failure. The PROBE-HF study. *J Card Fail*. 2009; **15**: 377–384.
 33. Gavazzi A, De Maria R, Grosu A, Iacovoni A, Fontana A, Gori M, Ferrari P, Canova P, Calabrese A, Filippi A, Rutili MR, Donzelli L, Parolini M, Senni M. Screening of asymptomatic left ventricular systolic dysfunction in a population sample at high cardiovascular risk in Lombardy (Italy): the DAVID-berg study. *G Ital Cardiol*. 2014; **15**: 313–322.
 34. Goode KM, Clark AL, Bristow JA, Sykes KB, Cleland JGF. Screening for left ventricular systolic dysfunction in high-risk patients in primary-care: a cost-benefit analysis. *Eur J Heart Fail* 2007. 2007; **9** (PG-1186-95): 1186–1195.
 35. Hebert K, Horswell R, Heidenreich P, Miranda J, Arcement L. Handheld ultrasound, B-natriuretic peptide for screening stage B heart failure. *South Med J*. 2010; **103**: 616–622.
 36. Lobos Bejarano JM, Horrillo Garcia C, Gonzalez-Gonzalez AI, Castellanos Rodriguez A, Diaz Sanchez S, Castellanos Maroto J, Rodriguez-Barrientos R, Garcia-Fernandez MA. Validity and usefulness of B-type natriuretic peptide (BNP) for early detection of left ventricular dysfunction in high-risk patients in primary care. *Aten Primaria*; **44**: 13–19.
 37. Luers C, Wachter R, Kleta S, Uhlir M, Koschack J, Scherer M, Binder L, Herrmann-Lingen C, Zapf A, Kulle B, Kochen MM, Pieske B. Natriuretic peptides in the detection of preclinical diastolic or systolic dysfunction. *Clin Res Cardiol*. 2010; **99**: 217–226.
 38. Murtagh G, Dawkins IR, O'Connell R, Badabhagn M, Patel A, Tallon E, O'Hanlon R, Ledwidge MT, McDonald KM. Screening to prevent heart failure (STOP-HF): expanding the focus beyond asymptomatic left ventricular systolic dysfunction. *Eur J Heart Fail*. 2012; **14**: 480–486.
 39. Mason JM, Hancock HC, Close H, Murphy JJ, Fuat A, de Belder M, Singh R, Teggert A, Wood E, Brennan G, Hussain N, Kumar N, Manshani N, Hodges D, Wilson D, Hungin APS. Utility of biomarkers in the differential diagnosis of heart failure in older people: findings from the heart failure in care homes (HFInCH) diagnostic accuracy study. *PLoS ONE*. 2013; **8**: 1–9.
 40. Abhayaratna WP, Marwick TH, Becker NG, Jeffery IM, McGill DA, Smith WT. Population-based detection of systolic and diastolic dysfunction with aminoterminal pro-B-type natriuretic peptide. *Am Heart J*. 2006; **152**: 941–948.
 41. Smith H, Pickering RM, Struthers A, Simpson I, Mant D. Biochemical diagnosis of ventricular dysfunction in elderly patients in general practice: observational study. *Br Med J*. 2000; **320**: 906–908.
 42. Vasani RS, Benjamin EJ, Larson MG, Leip EP, Wang TJ, Wilson PWF, Levy D. Plasma natriuretic peptides for community screening for left ventricular hypertrophy and systolic dysfunction: the Framingham heart study. *JAMA*; **2002**: 1252–1259.
 43. Cosin Aguilar J, Hernandez Martinez A, Diez Gil JL, Capdevila Carbonell C, Salvador Sanz A, Diago Torrent JL, Rivera Otero M, Paya Serrano R, Bertomeu Martinez V, Sogorb Garri F, Jordan Torrent A, Mainar Latorre L, Grau Jornet G, Marti Llinares S, Miro Palau V, Grupo de Estudio de la Disfuncion Ventricular Izquierda en la C. Value of NTproBNP concentration in an out-of-hospital adult population. *Rev Esp Cardiol*; **56**: 236–244.
 44. Costello-Boerrigter LC, Boerrigter G, Redfield MM, Rodeheffer RJ, Urban LH, Mahoney DW, Jacobsen SJ, Heublein DM, Burnett JC Jr. Amino-terminal pro-B-type natriuretic peptide and B-type natriuretic peptide in the general community: determinants and detection of left ventricular dysfunction. *J Am Coll Cardiol*. 2006; **47**: 345–353.
 45. de Lemos JA, McGuire DK, Khera A, Das SR, Murphy SA, Omland T, Drazner MH. Screening the population for left ventricular hypertrophy and left ventricular systolic dysfunction using natriuretic peptides: results from the Dallas heart study. *Am Heart J*. 2009; **157**: 746–753.
 46. Goetze JP, Mogelvang R, Maage L, Scharling H, Schnohr P, Sogaard P, Rehfeldt JF, Jensen JS. Plasma pro-B-type natriuretic peptide in the general population: screening for left ventricular hypertrophy and systolic dysfunction. *Eur Heart J*. 2006; **27**: 3004–3010.
 47. Groenning BA, Raymond I, Hildebrandt PR, Nilsson JC, Baumann M, Pedersen F. Diagnostic and prognostic evaluation of left ventricular systolic heart failure by plasma N-terminal pro-brain natriuretic peptide concentrations in a large sample of the general population. *Heart*. 2004; **90**: 297–303.
 48. Hedberg P, Lonnberg I, Jonason T, Nilsson G, Pehrsson K, Ringqvist I. Electrocardiogram and B-type natriuretic peptide as screening tools for left ventricular systolic dysfunction in a population-based sample of 75-year-old men and women. *Am Heart J*. 2004; **148**: 524–529.
 49. Luchner A, Burnett JC Jr, Jougasaki M, Hense HW, Heid IM, Muders F, Riegger GAJ, Schunkert H. Evaluation of brain natriuretic peptide as marker of left ventricular dysfunction and hypertrophy in the population. *J Hypertens*. 2000; **18**: 1121–1128.
 50. Ng LL, Loke I, Davies JE, Khunti K, Stone M, Abrams KR, Chin DT, Squire IB. Identification of previously undiagnosed left ventricular systolic dysfunction: community screening using natriuretic peptides and electrocardiography. *Eur J Heart Fail*. 2003; **5**: 775–782.
 51. Galasko GIW, Barnes SC, Collinson P, Lahiri A, Senior R. What is the most cost-effective strategy to screen for left ventricular systolic dysfunction: natriuretic peptides, the electrocardiogram, hand-held echocardiography, traditional echocardiography, or their combination? *Eur Heart J*. 2005; **27**: 193–200.
 52. Hobbs FDR. Reliability of N-terminal proBNP assay in diagnosis of left ventricular systolic dysfunction within representative and high risk populations. *Heart*. 2004; **90**: 866–870.
 53. McDonagh TA, Robb SD, Murdoch DR, Morton JJ, Ford I, Morrison CE, Tunstall-Pedoe H, McMurray JJ, Dargie HJ. Biochemical detection of left-ventricular systolic dysfunction. *Lancet*. 1998; **351**: 9–13.
 54. Mureddu GF, Tarantini L, Agabiti N, Faggiano P, Masson S, Latini R, Cesaroni G, Miceli M, Forastiere F, Scardovi AB, Ugucioni M, Boccanelli A. Evaluation of different strategies for identifying asymptomatic left ventricular dysfunction and pre-clinical (stage B) heart failure in the elderly. Results from “PRE-DICTOR”, a population based-study in Central Italy. *Epidemiology*. 2014; **15**: 1102–1112.
 55. Lukowicz TV, Fischer M, Hense HW, Doring A, Stritzke J, Riegger G, Schunkert H, Luchner A, Investigators M. BNP as a marker of diastolic dysfunction in the general population: importance of left ventricular hypertrophy. *Eur J Heart Fail*. 2005; **7**: 525–531.

56. Taylor CJ, Ordóñez-Mena JM, Jones NR, Roalfe AK, Lay-Flurrie S, Marshall T, Hobbs FDR. National trends in heart failure mortality in men and women, United Kingdom, 2000–2017. *Eur J Heart Fail.* 2021; **23**: 3–12.
57. Díaz JS, Muñoz E, Sènior JM. Natriuretic peptides in the detection of left ventricular dysfunction in a high risk population. A meta-analysis of diagnostic tests. *Rev Colomb Cardiol.* 2020; **27**: 548–559.
58. Homar V, Mirosevic S, Svab I, Lainscak M. Natriuretic peptides for heart failure screening in nursing homes: a systematic review. *Heart Fail Rev.* 2020.
59. Kievit RF, Gohar A, Hoes AW, Bots ML, van Riet EE, van Mourik Y, Bertens LC, Boonman-de Winter LJ, den Ruijter HM, Rutten FH. Efficient selective screening for heart failure in elderly men and women from the community: a diagnostic individual participant data meta-analysis. *Eur J Prev Cardiol.* 2018; **25**: 437–446.
60. Roalfe AK, Lay-Flurrie SL, Ordóñez-Mena JM, Goyder CR, Jones NR, Hobbs FDR, Taylor CJ. Long term trends in natriuretic peptide testing for heart failure in UK primary care: a cohort study. *Eur Heart J.* 2021; **42**: 881–891.
61. Braisch U, Koenig W, Rothenbacher D, Denkinger M, Friedrich N, Felix SB, Ittermann T, Dörr M, Dallmeier D. N-terminal pro brain natriuretic peptide reference values in community-dwelling older adults. *ESC Heart Fail.* 2022; **9**: 1703–1712.
62. Mueller C, McDonald K, de Boer RA, Maisel A, Cleland JGF, Kozhuharov N, Coats AJS, Metra M, Mebazaa A, Ruschitzka F, Lainscak M, Filippatos G, Seferovic PM, Meijers WC, Bayes-Genis A, Mueller T, Richards M, Januzzi JL. Heart failure Association of the European Society of Cardiology practical guidance on the use of natriuretic peptide concentrations. *Eur J Heart Fail.* 2019; **21**: 715–731.
63. Roberts E, Ludman AJ, Dworzynski K, Al-Mohammad A, Cowie MR, McMurray JJV, Mant J. The diagnostic accuracy of the natriuretic peptides in heart failure: systematic review and diagnostic meta-analysis in the acute care setting. *BMJ.* 2015; **350**: h910.
64. Stonestreet J, Woolley D, Uthman O, Arasaradnam RP, Chandrapalan S. Systematic review and meta-analysis: diagnostic accuracy of faecal immuno-chemical testing for haemoglobin (FIT) in detecting colorectal cancer for both symptomatic and screening population. *Acta Gastroenterol Belg.* 2019; **82**: 291–299.
65. Nambi V, Ballantyne CM, Hoogeveen RC, Agarwal SK, Panagiotakos DB, Wannamethee SG, Whincup PH, Kiechl S, Willeit J, Schett G, Santer P, Willeit P, Casas JP, Lawlor DA, DeFilippi C, Kronmal RA, Psaty BM, Cushman M, Nordestgaard BG, Olsen MH, Jørgensen T, de Lemos JA, McGuire DK, Das SR, Drazner MH, Salomaa V, Vartiainen E, Harald K, Zeller T, Levy D, Ninomiya T, Hata J, Kiyohara Y, Kauhanen J, Salonen JT, Laukkanen JA, Tuomainen TP, Ruskoaho H, Kistorp CN, Raymond I, Mueller T, Dieplinger B, Haltmayer M, Melander O, Heckbert SR, Lima JA, Luchner A, Stark K, Heid IM, Peters A, Andersson J, Jansson JH, Wennberg P, Rubattu S, Volpe M, Strazzullo P, Lind L, Venge P, Lindahl B, de Boer RA, Bakker SJL, Gansevoort RT, Kee F, Evans A, Yarnell JWG, Trompet S, Jukema JW, Stott DJ, de Craen AJM, Rosenberg J, Hildebrandt PR, Gustafsson F, Schou M, Daniels LB, Barrett-Connor E, Maisel AS, Judd S, Safford MM, Howard VJ, Zakai NA, Gudnason V, Aspelund T, Eiriksdottir G, Agnarsson U, Andresdottir MB, Kavousi M, Hofman A, Ligthart S, van den Meiracker AH, Franco OH, Dehghan A, van Rooij FJA, Ikram MA, Kizer JR, Best LG, Devereux RB, Umans JG, Ärnlöv J, Zethelius B, Lannfelt L, Giedraitis V, Cook NR, Manson JAE, Everett BM, Ridker PM, Pradhan AD, Sattar N, Ford I, Packard CJ, Welsh P. Natriuretic peptides and integrated risk assessment for cardiovascular disease: an individual-participant-data meta-analysis. *Lancet Diabetes Endocrinol.* 2016; **4**: 840–849.
66. James B, Greening N, Toms N, Steiner M, Evans R. Is there benefit from proactive case-detection of left ventricular systolic dysfunction (LVSD) using BNP in patients with advanced COPD? In *12 Rehabilitation and Chronic Care*. European Respiratory Society; 2016. p PA3781.